Eli Lilly
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Eli Lilly and other ETFs, options, and stocks.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
LLY News
Pharmaceutical titan Eli Lilly (LLY) represents one of our country’s most storied companies. Since its founding more than 140 years ago, Lilly has come up with...
Eli Lilly and Co. (NYSE:LLY), a pharmaceutical giant known for its innovative drugs, is trading near its all-time high after exceeding earnings expectations. De...
Loading... Loading... Eli Lilly And Co’s LLY much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U.S. for...
Analyst ratings
72%
of 29 ratingsMore LLY News
As great of an investment as Eli Lilly (NYSE: LLY) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent oppo...
Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$905 With US$754 share price, Eli Lilly appears to be trading clos...
It's hard to overstate just how successful the expansions of new diabetes treatments into the weight management arena have been for the companies that sell them...
When a company's big plans go awry, it's always worth reconsidering the merits of an investment. On March 8, regulators at the Food and Drug Administration (FDA...
U.S. pharma giant Eli Lilly announced Wednesday that it is partnering with Amazon to deliver its weight loss drug Zepbound straight to users’ doors. Advertis...
There's an old saying that "politics makes strange bedfellows." We could add that business sometimes does too. Pharmaceutical giant Eli Lilly (NYSE: LLY) and e...
According to Reuters, biotech company Eli Lilly’s (NYSE:LLY) new weight-loss medication Zepbound outperformed Novo Nordisk’s (NYSE:NVO) Wegovy in new U.S. presc...